Lupin's Pithampur Unit 2 Under Scrutiny: USFDA Issues Form 483 with Four Key Observations

Lupin Unleashes Affordable Overactive Bladder Treatment in the U.S. Market

Lupin's Bold Move: Rs 1970 Crore Visufarma Acquisition Set to Reshape Ophthalmic Market

Lupin's Visionary Move: Eyeing European Domination with VisuFarma Acquisition

Lupin's Latest Triumph: US FDA Greenlight for HIV Drug Ignites Stock Rally

Market Movers: Decoding the Buzz Around iValue, Polycab, Tata Steel, and More

Lupin Achieves Major Milestone: USFDA Grants Tentative Approval for Generic HIV Treatment Drug

Decoding the Paradox: Why Indian Pharma Stocks Are Plummeting Even After US Tariff Relief

India's Pharma Vision: Charting a Course for Global R&D Leadership